LDL cholesterol can drop well below the levels most doctors traditionally targeted, and clinical trial data now shows cardiovascular benefits continuing down to levels as low as 10 mg/dL or even lower. The natural, physiologically normal range for LDL appears to be 50 to 70 mg/dL, based on studies of newborns, hunter-gatherer populations, wild primates, and other mammals that don’t develop atherosclerosis. Modern medicine can push levels far below that range, and while the heart benefits are clear, questions about other risks at extremely low levels deserve a closer look.
What Counts as “Normal” LDL
Most lab reports flag LDL cholesterol above 100 mg/dL as elevated and label anything under 100 as “optimal.” But that reference range reflects the average in industrialized populations, not what human biology was built around. Newborn humans typically have LDL levels between 50 and 70 mg/dL. Hunter-gatherer societies that eat traditional diets land in the same range. So do free-living primates and other wild mammals. None of these groups develop plaque buildup in their arteries.
This has led some cardiologists to argue that an LDL of 50 to 70 mg/dL is the true biological baseline, and that the levels most adults walk around with in Western countries are chronically elevated rather than “normal.”
How Low Trials Have Actually Gone
The biggest push toward rock-bottom LDL levels came from trials of PCSK9 inhibitors, a class of injectable medications that dramatically lower LDL when added to statin therapy. In the FOURIER trial of over 27,500 patients with stable heart disease, the treatment group reached a median LDL of 30 mg/dL. Forty-two percent of participants dropped below 25 mg/dL. The ODYSSEY OUTCOMES trial, which enrolled nearly 19,000 patients after a recent heart attack, brought the treatment group’s median LDL down to 40 mg/dL within one month.
What made these results remarkable is that heart attack and stroke risk kept declining as LDL went lower, with no floor in sight. In a long-term follow-up of FOURIER participants, cardiovascular events continued to drop at LDL levels below 20 mg/dL and even below 10 mg/dL. In the exploratory group with the very lowest levels, the median LDL was just 7 mg/dL.
Some People Are Born With Very Low LDL
Nature has already run this experiment. A small percentage of people carry genetic mutations that reduce the activity of a protein called PCSK9, which normally recycles the receptors that clear LDL from the blood. With less PCSK9 activity, their bodies remove LDL more efficiently, and they walk through life with naturally lower levels.
A landmark study published in the New England Journal of Medicine found that people with one type of these mutations had LDL levels about 40 mg/dL lower than average and an 88 percent reduction in coronary heart disease. A milder variant lowered LDL by about 20 mg/dL and cut heart disease risk in half. These individuals showed no obvious health problems from their low LDL, and their lifelong exposure to reduced levels appeared to compound the cardiovascular benefit far beyond what short-term treatment achieves.
Why Your Cells Don’t Starve
Cholesterol is essential. Every cell in your body uses it to build and maintain its outer membrane, and it serves as the raw material for vitamin D and key hormones. So it’s reasonable to wonder: if LDL drops to single digits, do your cells run out of cholesterol?
The answer is no, because cells don’t depend solely on LDL deliveries. Every cell can manufacture its own cholesterol internally. When circulating LDL drops, cells activate a sensor system that ramps up their own cholesterol production. The key enzyme in this process becomes more stable and more active when cholesterol supply from the bloodstream falls. Some tissues can even switch to an alternative production pathway that works without oxygen, which is useful in low-oxygen environments like certain glands and deeper tissues. This built-in backup means that even at very low circulating LDL, cells maintain the cholesterol they need for structure and function.
The Brain Safety Question
One of the most persistent concerns about very low LDL is cognitive function. Cholesterol is abundant in the brain, and early anecdotal reports linked statins to memory complaints, leading to worry that aggressive LDL lowering could harm thinking and memory over time.
The most rigorous test of this came from a dedicated cognitive sub-study of the FOURIER trial called EBBINGHAUS, which followed 473 patients for over five years (up to 7.2 years from the original enrollment). The median LDL across these patients was 35 mg/dL, with a quarter of them below 21 mg/dL. Researchers found no change in executive function scores regardless of how low LDL dropped or how long patients maintained those levels. Patients who had been on PCSK9 inhibitor therapy from the start performed identically to those who started later. The conclusion: very low LDL achieved through medication was not associated with cognitive impairment over long-term follow-up.
One caveat is that these participants were mostly white men in their early 60s without pre-existing dementia risk. Whether the same safety profile holds for older adults or those already showing cognitive decline hasn’t been fully established.
Hemorrhagic Stroke: A Real Signal
The one area where very low LDL raises a legitimate red flag is bleeding in the brain. Observational data has consistently found that people with LDL below 70 mg/dL have a higher rate of hemorrhagic stroke (the type caused by a burst blood vessel, not a clot). Compared to people with LDL between 70 and 99 mg/dL, those with LDL of 50 to 69 mg/dL had a 65 percent higher risk. For people with LDL below 50 mg/dL, the risk was 2.7 times higher.
This doesn’t mean low LDL directly causes brain bleeds. Cholesterol is a component of blood vessel walls, and extremely low levels may make small vessels in the brain more fragile. But it’s also possible that other factors, like liver disease or malnutrition, both lower LDL and independently raise hemorrhagic stroke risk. The absolute number of hemorrhagic strokes is small compared to the heart attacks and clot-based strokes prevented by lowering LDL, so for most people with cardiovascular disease, the math still favors aggressive treatment. But for someone who already has risk factors for brain bleeds, like uncontrolled high blood pressure, this tradeoff matters.
Hormone Production at Very Low Levels
Cholesterol is the starting material for cortisol, testosterone, estrogen, and other steroid hormones. Both the adrenal glands and the reproductive organs primarily pull from circulating LDL to make these hormones, which raises a natural question about what happens when LDL is pushed to very low levels.
In practice, the large clinical trials have not reported significant drops in hormone levels or symptoms of hormone deficiency. But the evidence here is thinner than for cardiovascular outcomes or cognition. Most trials weren’t specifically designed to track hormone changes, and statins (which are typically used alongside PCSK9 inhibitors) both lower circulating LDL and reduce cholesterol production inside cells, a double effect that could theoretically matter. For now, hormone disruption hasn’t emerged as a clinical problem in trial populations, but it remains an area where long-term data in broader groups would be valuable.
What Current Guidelines Recommend
The 2025 ACC/AHA guidelines for patients who’ve had a heart attack or acute coronary event recommend high-intensity statin therapy for everyone, with the option to add other medications from the start. If LDL stays at or above 70 mg/dL despite maximum statin doses, guidelines recommend adding a second agent. If LDL lands between 55 and 70 mg/dL, further intensification is considered reasonable for high-risk patients.
Notably, the guidelines don’t set a lower limit. There’s no LDL level at which they say “that’s low enough, stop treating.” This reflects the trial data showing continued benefit at progressively lower levels. For people without heart disease, the treatment thresholds are higher and the approach is less aggressive, but the trend in cardiology is clearly toward lower targets than were standard even a decade ago.